NicOx.... in attesa di..... (10 lettori)

[tradermen]

5 Not yet recruiting A Study Evaluating the Long-Term Safety of Latanoprostene Bunod Ophthalmic Solution 0.024%, in Japanese Subjects With Open-Angle Glaucoma or Ocular Hypertension
Conditions: Glaucoma; Ocular Hypertension
Intervention: Drug: Latanoprostene bunod


This study is not yet open for participant recruitment.
Verified July 2013 by Bausch & Lomb Incorporated
Sponsor:
Bausch & Lomb Incorporated
Information provided by (Responsible Party):
Bausch & Lomb Incorporated
ClinicalTrials.gov Identifier:
NCT01895972
First received: July 3, 2013
Last updated: July 8, 2013
Last verified: July 2013
History of Changes
Estimated Enrollment: 130
Study Start Date: July 2013
Estimated Study Completion Date: November 2013
Estimated Primary Completion Date: October 2013 (Final data collection date for primary outcome measure)

6 Not yet recruiting Efficacy of Latanoprostene Bunod in Lowering Intraocular Pressure in Japanese Healthy Male Volunteers
Condition: Intraocular Pressure
Intervention: Drug: Latanoprostene bunod


This study is not yet open for participant recruitment.
Verified July 2013 by Bausch & Lomb Incorporated
Sponsor:
Bausch & Lomb Incorporated
Information provided by (Responsible Party):
Bausch & Lomb Incorporated
ClinicalTrials.gov Identifier:
NCT01895985
First received: July 3, 2013
Last updated: July 10, 2013
Last verified: July 2013
History of Changes


Estimated Enrollment: 24
Study Start Date: July 2013
Estimated Study Completion Date: September 2013
Estimated Primary Completion Date: August 2013 (Final data collection date for primary outcome measure

 

[tradermen]

Amgen close to buying Onyx for $125 per share: sources







Sat Aug 24, 2013 5:34pm EDT

(Reuters) - Amgen Inc (AMGN.O) is close to buying Onyx Pharmaceuticals Inc (ONXX.O) for $125 per share, or more than $10 billion, in a deal that is expected to be announced as soon as Monday, two people familiar with the matter said on Saturday.

A deal, which is still being finalized and would require board approval from both companies, would represent the fifth-largest biotechnology deal in history.

The proposed takeover would value Onyx at 13 times the company's expected revenues for next year, one of the richest valuations in biotech takeovers, one of the people said.

The people asked not to be identified because the matter is not public. Representatives for Amgen and Onyx could not be immediately reached for comment.

The acquisition of Onyx would give Amgen full rights to Kyprolis, the new multiple myeloma drug that analysts expect to reach annual peak sales in excess of $2 billion.

Amgen would also gain a revenue stream from the liver and kidney cancer drug Nexavar that Onyx shares with Bayer AG, as well as royalty payments on Bayer's much newer colon cancer drug Stivarga and potential future royalties on an experimental breast cancer drug being developed by Pfizer.

A deal in the $10 billion range would be Amgen's biggest since its $16 billion acquisition of Immunex in 2001 that gave it the rheumatoid arthritis drug, Enbrel, which is one of Amgen's most important, biggest-selling products.

It would be by far the biggest deal under CEO Bob Bradway, who took over the top spot in May 2012. He has done a handful of much smaller deals, the biggest to date being a $1.16 billion acquisition of Micromet.

 

[relavo]

Buongiorno a tutti, detrattori compresi; è vero con l'Adenoplus stiamo facendo un fatturato ridicolo e gli altri prodotti andranno in commercio solo con la fine del 2013/ inizio 2014 e anche da loro c'è da aspettarsi ben poco. In questo momento non ho alcuna certezza ma solo tre speranze:
1) Merck passa in fase clinica II
2) il Naproxcinod per l'artrosi al gionocchio o per la Duchenne trova un partner
3) Bausch + Lomb chiude con successo la fase III del NO-xalatan

Chissà se almeno una delle tre si realizzerà ?

e chissà se domani nevica a Rimini?

 

[Miki53]

Appunto ...

e chissà se domani nevica a Rimini?

La somma di tre improbabilità non fà una probabilità più alta ...

poi ... il signore lo volesse ....!!

 

[PIZZODIGINO]

Il formaggio gratis si trova solo nelle trappole per i topi.

 

[Zohar]

Il formaggio gratis si trova solo nelle trappole per i topi.

Di mangiatori a sbafo mi sembra ce ne siano già abbastanza ... anche senza trappole ...

 

[PIZZODIGINO]

SARASOTA, Fla.(August 20,2013)
–​

Rapid Pathogen Screening,Inc.​

​

​

​

(RPS®),today announced that it has brought on Glenn Gerstenfeld​

as its vice president of quality and regulatory affairs and​

Jennifer Frisbie as the director of
marketing for primary care and government channels.

RPS rafforza il suo board; ma che fine hanno fatto i due prodotti per i quali Nicox stà pagando metà dei costi di sviluppo ?​

 

[guly]

e chissà se domani nevica a Rimini?

molto piu' propabile.

 

[guly]

Di mangiatori a sbafo mi sembra ce ne siano già abbastanza ... anche senza trappole ...

ne conosco uno.ma non pposso fare nomi.bravissimo debbo dire molto mimetico

 

[Zohar]

ne conosco uno.ma non pposso fare nomi.bravissimo debbo dire molto mimetico